FDA Grants Mirvetuximab Full Approval for Ovarian Cancer FDA Grants Mirvetuximab Full Approval for Ovarian Cancer
Mirvetuximab soravtansine-gynx (Elahere) is approved for patients with folate receptor –alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Epithelial Cancer | Fallopian Tube Cancer | Grants | Health | Hematology | Ovarian Cancer | Ovaries | Peritoneal Cancer